Status:

COMPLETED

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Lead Sponsor:

Janssen-Ortho Inc., Canada

Collaborating Sponsors:

Ontario Clinical Oncology Group (OCOG)

Conditions:

Prostate

Carcinoma

Eligibility:

MALE

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia in hormone-refractory (no...

Detailed Description

Anemia is a common problem experienced by patients with malignancy. Although cancer treatment such as systemic chemotherapy is an obvious cause, many cancer patients are anemic at presentation. Estima...

Eligibility Criteria

Inclusion

  • Patients with histological confirmed adenocarcinoma of the prostate or patients who have metastatic carcinoma of presumptive prostate origin as manifest by the presence of sclerotic bony metastases and a serum PSA level greater than the upper limit of normal
  • Hemoglobin level at or below 120 g/L
  • ECOG (Eastern Cooperative Oncology Group) Performance status of 0-2.

Exclusion

  • No known or suspected CNS metastasis (Cancer that has spread from the original (primary) tumor to the central nervous system)
  • No other active concurrent malignancy, other than the underlying prostate cancer which is expected to influence QoL
  • No blood transfusions within the last 14 days and no previous use of erythropoietin (i.e., that would impact baseline Hb)
  • No anemia due to factors other than cancer/radiotherapy (i.e., hemolysis or gastrointestinal bleeding, evidence of untreated folate or vitamin B12 deficiency)
  • No history of uncontrolled hypertension or diastolic blood pressure greater than 100 mmHg
  • No mental incompetence, including psychiatric or addictive disorders which would preclude meaningful completion of quality-of-life questionnaires.

Key Trial Info

Start Date :

December 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2006

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT00364455

Start Date

December 1 2002

End Date

March 1 2006

Last Update

April 27 2010

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.